Dyne upsizes ATM offering from $200M to $300M; $101.2M already sold

Dyne Therapeutics, Inc.

Filed prospectus supplement to sell up to $300M common stock via ATM with Jefferies, up from $200M.
As of Nov 12, 2024, aggregate gross proceeds of ~$101.2M already sold under prior $200M program.
New supplement replaces prior prospectus; no further sales will be made under the old one.
Shares registered under existing shelf registration statement; legal opinion included as exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.